Harnessing the ID in glioma

Gliomas are the most common form of brain tumor. They are highly aggressive and effective treatments are not currently available. The tumors contain glioma initiating cells (GICs), a population that is highly similar to neural stem cells. GICs drive tumor progression and must stay in a particular extracellular niche in order to maintain their cancer-promoting, stem cell-like characteristics.

In this issue of the , researchers led by Antonio Iavarone at Columbia University report on the role of ID proteins in glioma. ID proteins allow stem cells to stay anchored in a particular extracellular niche.

Using a mouse model of glioma, Iavarone and colleagues found that ID proteins were also responsible for retaining GICs in the extracellular niche that allowed them to maintain their cancer promoting properties. In human glioma patients, the expression of a group of Id-regulated genes was correlated with clinical outcomes.

These results suggest that ID proteins are important regulators of glioma and may be suitable therapeutic targets.

More information: Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis, Journal of Clinical Investigation, 2012.

add to favorites email to friend print save as pdf

Related Stories

'Housekeeping' mechanism for brain stem cells discovered

Apr 22, 2012

Researchers at Columbia University Medical Center (CUMC) have identified a molecular pathway that controls the retention and release of the brain's stem cells. The discovery offers new insights into normal and abnormal neurologic ...

To combat deadly brain cancer, target the stem cells

Jul 07, 2011

Researchers have uncovered a new target that could stop the growth of glioblastoma, a deadly form of brain cancer. In the July 8th issue of the journal Cell, a Cell Press publication, a new study identifies an enzyme found ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.